Ectopia Lentis

Understanding the underlying causes and mechanisms of lens displacement is critical for advancing therapeutic interventions. Harnessing cutting-edge research and a deep understanding of genetic, molecular, and preclinical aspects, Protheragen offers a comprehensive portfolio of therapeutic solutions tailored to Ectopia Lentis.

Overview of Ectopia Lentis

Ectopia lentis, a condition characterized by the displacement of the eye's crystalline lens from its normal position, presents a significant challenge in ophthalmology. This dislocation can be partial, known as subluxation, or complete, termed luxation. The condition can lead to severe visual impairments, including high refractive error, irregular astigmatism, and decreased best-corrected visual acuity (BCVA). Ectopia lentis is often associated with systemic connective tissue disorders, such as Marfan syndrome, Weill-Marchesani syndrome, and homocystinuria, which underscores the complexity of its management.

Fig.1 Statistics of congenital ectopia lentis (CEL) in different age subgroups. (Jin G.M., et al., 2018)

Diagnostics Development for Ectopia Lentis

• Genetic and Molecular Diagnostics
  A cornerstone of Ectopia Lentis diagnostics lies in identifying the genetic markers and mutations responsible for its occurrence. For instance, Marfan syndrome is linked to mutations in the FBN1 gene, which affect the integrity of connective tissues. Molecular diagnostics leveraging next-generation sequencing can provide significant insights into the hereditary aspects of Ectopia Lentis, facilitating early detection and family counseling.
• Biochemical Diagnostics
  Biochemical assays for conditions like homocystinuria, caused by cystathionine beta-synthase deficiency, add another layer of diagnostic capability. These assays can detect elevated levels of plasma homocysteine, a key marker for differential diagnosis among Ectopia Lentis-associated disorders.

Therapeutics Development for Ectopia Lentis

Our Services

At the cutting edge of ocular therapeutics, Protheragen is pioneering the development of innovative therapeutics for ectopia lentis. We adopt a comprehensive, multidisciplinary strategy that integrates advanced research with extensive preclinical capabilities. Our expertise spans the entire drug discovery and development continuum, starting from the identification of therapeutic targets to the execution of preclinical assessments.

Target Identification and Validation Services for Ectopia Lentis

Protheragen supports the discovery and rigorous validation of novel therapeutic targets for ectopia lentis, focusing on genes, proteins, and signaling pathways that regulate ciliary zonule development, extracellular matrix assembly, fibrillin-1 homeostasis, and inflammatory or oxidative stress responses. Our target validation services include in silico target prioritization using genomic and transcriptomic datasets from human ectopia lentis patients, in vitro functional validation in primary ciliary epithelial cells and zonular fibroblasts, and ex vivo validation in human donor ocular tissues.

We perform genetic perturbation studies (CRISPR-Cas9 knockout/knockin, RNA interference) to confirm target involvement in zonular structural integrity and lens stability, alongside biochemical assays to quantify protein–protein interactions (e.g., fibrillin-1–ADAMTSL4 binding), microfibril assembly, and extracellular matrix cross-linking. For syndromic ectopia lentis, we validate targets linked to FBN1, TGF-β signaling, and homocysteine metabolism; for isolated disease, we focus on ADAMTSL4, ADAMTS17, and other zonule-specific genes. Protheragen also provides comparative target validation across multiple ectopia lentis subtypes to identify broadly applicable targets or subtype-specific therapeutic opportunities, ensuring clients pursue high-confidence, disease-relevant targets with strong translational potential.

In Vitro and Ex Vivo Model Development and Screening Services

We offer custom development and utilization of physiologically relevant in vitro and ex vivo models for ectopia lentis drug screening, mechanism of action studies, and lead optimization. Our in vitro models include primary human ciliary epithelial cells, immortalized zonular fibroblast cell lines carrying patient-derived FBN1 or ADAMTSL4 mutations, and 3D microfluidic co-culture systems that recapitulate the ciliary body–zonule–lens microenvironment. These models enable high-throughput screening of small-molecule libraries, biologic candidates, and gene therapy vectors to identify compounds that enhance fibrillin-1 expression, promote microfibril assembly, reduce ECM degradation, or improve zonular mechanical properties.

For ex vivo studies, Protheragen maintains a bank of wild-type and genetically modified mammalian lens–zonule–ciliary body explants that preserve native tissue architecture and biomechanics. These explants allow direct assessment of drug effects on zonular integrity, lens stability, and ECM organization under controlled ex vivo conditions, bridging in vitro screening and in vivo efficacy testing. We provide quantitative readouts including confocal imaging of microfibril structure, immunofluorescence quantification of target protein expression, biomechanical tensile testing of zonular fibers, and ELISA-based measurement of ECM turnover markers—all optimized for sensitive detection of therapeutic activity in ectopia lentis-relevant tissues.

In Vivo Efficacy and Pharmacodynamic (PD) Services

Protheragen delivers specialized in vivo efficacy testing services using genetically validated animal models that recapitulate key features of human ectopia lentis, including lens displacement, zonular degeneration, and ECM pathology. Our model portfolio includes Fbn1 mutant mouse lines replicating Marfan syndrome–associated ectopia lentis, Adamtsl4 knockout models for isolated autosomal recessive disease, and mechanically induced zonular injury models for traumatic or degenerative ectopia lentis. These models enable rigorous evaluation of therapeutic efficacy in clinically relevant contexts, with longitudinal monitoring of lens position, zonular structure, and ocular function.

Our in vivo services include long-term efficacy studies to assess disease modification (not just symptomatic relief), with endpoints including in vivo slit-lamp imaging, optical coherence tomography (OCT) of the anterior segment, ex vivo histomorphometry of zonular fibers, immunohistochemical analysis of ECM components, and biomechanical testing of isolated zonules. We support multiple administration routes relevant to ocular therapy, including topical eye drops, subconjunctival injection, intravitreal delivery, and systemic dosing, with tailored pharmacodynamic sampling to measure target engagement, biomarker modulation, and disease reversal. Protheragen's in vivo studies are designed to meet ICH and FDA guidelines for preclinical efficacy evaluation in rare ocular diseases, providing clients with robust data to support lead candidate selection and advancement.

Ocular Pharmacokinetic (PK) and Biodistribution Services

We provide specialized ocular pharmacokinetic and biodistribution services for ectopia lentis therapeutics, quantifying drug exposure and tissue distribution in ocular compartments critical to efficacy: aqueous humor, vitreous humor, ciliary body, lens capsule, and zonular fibers. Protheragen uses validated analytical methods (LC–MS/MS, ELISA, quantitative fluorescence imaging) to measure drug concentrations following topical, intravitreal, subconjunctival, or systemic administration, generating full PK profiles including Cmax, Tmax, half-life, area under the curve (AUC), and tissue retention time.

For gene therapy and nucleic acid therapeutics, we offer quantitative PCR (qPCR) and digital PCR (dPCR) to measure vector copy number and transgene expression in target ocular tissues, alongside fluorescence in situ hybridization (FISH) for cellular-level biodistribution mapping. Our ocular PK studies include dose-proportionality assessment, formulation comparison, and duration of exposure analysis to optimize dosing regimens for sustained target engagement in the ciliary zonule. These data are critical for establishing therapeutic dose ranges, minimizing off-target exposure, and supporting IND filings for ectopia lentis therapies.

Preclinical Safety and Toxicology Services

Protheragen provides ocular-specific and systemic safety assessment services to characterize the preclinical safety profile of ectopia lentis therapeutics, including acute, subacute, and chronic toxicology studies in rodent and non-rodent species. Our ocular safety evaluations include detailed ophthalmic examinations (slit-lamp, fundoscopy, OCT), clinical chemistry, hematology, and histopathological analysis of ocular tissues (cornea, iris, ciliary body, retina, optic nerve) to detect local irritation, inflammation, or structural damage.

We assess potential off-target effects related to mechanism of action, including TGF-β pathway modulation, ECM modification, and genetic vector-related immune responses. For gene therapies, we include biodistribution to non-ocular tissues, germline risk assessment, and immune response profiling (anti-vector antibodies, cytokine analysis). All safety studies are conducted in compliance with GLP principles where required, with comprehensive pathology reports and statistical analysis to define no-observed-adverse-effect levels (NOAEL) and maximum tolerated dose (MTD) for clinical starting dose selection.

Formulation Development and Optimization Services

We offer customized formulation development services for ectopia lentis therapeutics, focusing on ocular bioavailability, stability, and tissue penetration to the ciliary zonule. Our formulation experts optimize small molecules, peptides, proteins, and nucleic acids for topical, intravitreal, or sustained-release delivery, including aqueous eye drops, mucoadhesive formulations, liposomal nanoparticles, and hydrogel-based depot systems. We characterize formulation performance via in vitro release testing, ex vivo corneal and scleral penetration assays, and in vivo PK studies to ensure sufficient drug delivery to the target zonular tissue.

For gene therapy and regenerative medicine candidates, we support vector formulation, buffer optimization, and cryopreservation development to maintain potency and stability during storage and administration. Protheragen also provides compatibility testing with ocular delivery devices and scalability assessment for preclinical and clinical manufacturing, ensuring formulations are robust, reproducible, and suitable for advancement to clinical testing.

Mechanism of Action (MoA) and Biomarker Development Services

Protheragen supports comprehensive mechanism of action studies to define how ectopia lentis therapeutics restore zonular integrity and stabilize the lens, including transcriptomic, proteomic, and phosphoproteomic profiling to identify downstream signaling pathways and molecular changes induced by treatment. We quantify changes in fibrillin-1 deposition, microfibril assembly, ECM cross-linking, protease activity, and inflammatory mediator levels to establish a clear mechanistic link between drug exposure and therapeutic effect.

In parallel, we develop and validate exploratory biomarkers for ectopia lentis, including aqueous humor proteins, circulating microRNAs, and ocular imaging parameters (zonular thickness, lens displacement distance) that correlate with disease severity and treatment response. These biomarkers enable quantitative assessment of therapeutic efficacy in preclinical models and support clinical trial endpoint design, accelerating clinical translation and regulatory acceptance.

Diagnostics Development

• Karyotype Analysis Service
• Omics Analysis Service
• Biomarker Development Service
• Artificial Intelligence Service

Therapeutic Development

• Small Molecule Drug
• Cell Therapy
• Gene Therapy
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic Protein

Preclinical Research

• Pharmacodynamics Study Services
• Pharmacokinetics Study Services
• Drug Safety Evaluation Services

Disease Models

Fbn1 Conditional Knockout Mouse Models
Construction Method: Targeted deletion of fibrillin-1 (Fbn1) in the non-pigmented ciliary epithelium (NPCE) using Cre-Lox technology.

Our laboratories conduct rigorous in vitro and in vivo studies to evaluate the efficacy and safety of potential therapeutics. These studies are designed to mimic the human disease state as closely as possible, providing valuable insights into how new therapeutics may perform in actual cases. If you are interested in our services, please feel free to contact us.

References

• Jin, Guang-Ming, et al. "Trends and characteristics of congenital ectopia lentis in China." International journal of ophthalmology 11.9 (2018): 1545.
• Rissardo, Jamir Pitton, and Ana Letícia Fornari Caprara. "Ectopia lentis differential diagnosis." The Pan-American Journal of Ophthalmology 2.1 (2020): 24.